Shanghai Haohai Biological Technology Co., Ltd. (6826.HK)
- Previous Close
23.350 - Open
23.350 - Bid 23.350 x --
- Ask 23.500 x --
- Day's Range
23.150 - 23.550 - 52 Week Range
21.700 - 42.950 - Volume
115,300 - Avg. Volume
591,917 - Market Cap (intraday)
11.393B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
12.03 - EPS (TTM)
1.950 - Earnings Date Aug 14, 2025 - Aug 18, 2025
- Forward Dividend & Yield 1.08 (4.61%)
- Ex-Dividend Date Jun 17, 2025
- 1y Target Est
42.99
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, the company offers medical aesthetics products, including Matrifill, a first-generation hyaluronic acid (HA) dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; genetic-engineering preparations for epidermal repair; and radio frequency devices and laser equipment. Additionally, it is involved in the research and development, consultation, and services of biological engineering and pharmaceutical products, and related technology transfer activities; manufacture and sale of biological reagents, biologicals, and biological materials; manufacture and sale of intraocular lens and related products; sale machines of medical aesthetics, professional life cosmetology, and home cosmetology; sale of ophthalmology products; and provision of other machines and accessories. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
www.3healthcare.comRecent News: 6826.HK
View MorePerformance Overview: 6826.HK
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6826.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6826.HK
View MoreValuation Measures
Market Cap
11.39B
Enterprise Value
8.93B
Trailing P/E
12.03
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.88
Price/Book (mrq)
0.89
Enterprise Value/Revenue
3.08
Enterprise Value/EBITDA
11.97
Financial Highlights
Profitability and Income Statement
Profit Margin
15.58%
Return on Assets (ttm)
3.22%
Return on Equity (ttm)
6.09%
Revenue (ttm)
2.65B
Net Income Avi to Common (ttm)
413.22M
Diluted EPS (ttm)
1.950
Balance Sheet and Cash Flow
Total Cash (mrq)
2.66B
Total Debt/Equity (mrq)
7.60%
Levered Free Cash Flow (ttm)
247.88M